154 related articles for article (PubMed ID: 35039611)
1. PLOD3 regulates the expression of YAP1 to affect the progression of non-small cell lung cancer via the PKCδ/CDK1/LIMD1 signaling pathway.
Li WH; Huang K; Wen FB; Cui GH; Guo HZ; Zhao S
Lab Invest; 2022 Apr; 102(4):440-451. PubMed ID: 35039611
[TBL] [Abstract][Full Text] [Related]
2. PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway.
Baek JH; Yun HS; Kwon GT; Lee J; Kim JY; Jo Y; Cho JM; Lee CW; Song JY; Ahn J; Kim JS; Kim EH; Hwang SG
Cell Death Dis; 2019 Feb; 10(3):156. PubMed ID: 30770789
[TBL] [Abstract][Full Text] [Related]
3. LIMD1-AS1 suppressed non-small cell lung cancer progression through stabilizing LIMD1 mRNA via hnRNP U.
Pan J; Tang Y; Liu S; Li L; Yu B; Lu Y; Wang Y
Cancer Med; 2020 Jun; 9(11):3829-3839. PubMed ID: 32239804
[TBL] [Abstract][Full Text] [Related]
4. LIMD1 phosphorylation in mitosis is required for mitotic progression and its tumor-suppressing activity.
Zhou J; Zhang L; Zhou W; Chen Y; Cheng Y; Dong J
FEBS J; 2019 Mar; 286(5):963-974. PubMed ID: 30600590
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression.
Xie D; Li J; Wei S; Qi P; Ji H; Su J; Du N; Zhang X
Mol Cell Probes; 2020 Oct; 53():101608. PubMed ID: 32585183
[TBL] [Abstract][Full Text] [Related]
6. Lycorine inhibited the cell growth of non-small cell lung cancer by modulating the miR-186/CDK1 axis.
Li L; Zhang Z; Yang Q; Ning M
Life Sci; 2019 Aug; 231():116528. PubMed ID: 31176784
[TBL] [Abstract][Full Text] [Related]
7. A Human Pan-Cancer System Analysis of Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 (PLOD3).
Gong S; Duan Y; Wu C; Osterhoff G; Schopow N; Kallendrusch S
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576068
[TBL] [Abstract][Full Text] [Related]
8. PLOD3 promotes lung metastasis via regulation of STAT3.
Baek JH; Yun HS; Kwon GT; Kim JY; Lee CW; Song JY; Um HD; Kang CM; Park JK; Kim JS; Kim EH; Hwang SG
Cell Death Dis; 2018 Nov; 9(12):1138. PubMed ID: 30442941
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.
Davidson K; Grevitt P; Contreras-Gerenas MF; Bridge KS; Hermida M; Shah KM; Mardakheh FK; Stubbs M; Burke R; Casado P; Cutillas PR; Martin SA; Sharp TV
Cell Death Dis; 2021 Nov; 12(11):1075. PubMed ID: 34764236
[TBL] [Abstract][Full Text] [Related]
10. PLOD3 is Upregulated in Gastric Cancer and Correlated with Clinicopathologic Characteristics.
Wang B; Xu L; Ge Y; Cai X; Li Q; Yu Z; Wang J; Wang Y; Lu C; Wang D; Wang Y; Chen X; Gu Y
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775879
[TBL] [Abstract][Full Text] [Related]
11. Restraint of chaperonin containing T-complex protein-1 subunit 3 has antitumor roles in non-small cell lung cancer via affection of YAP1.
Shi H; Zhang Y; Wang Y; Fang P; Liu Y; Li W
Toxicol Appl Pharmacol; 2022 Mar; 439():115926. PubMed ID: 35182550
[TBL] [Abstract][Full Text] [Related]
12. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
He W; Zhang Y; Xia S
Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of lncRNA NCK1-AS1 predicts poor prognosis and contributes to non-small cell lung cancer proliferation by regulating CDK1.
Zha LF; Zhang LD; Pan HM; Ma HD
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1351-1357. PubMed ID: 33629305
[TBL] [Abstract][Full Text] [Related]
14. ITGB1 enhances the Radioresistance of human Non-small Cell Lung Cancer Cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal Transition.
Li Y; Sun C; Tan Y; Zhang H; Li Y; Zou H
Int J Biol Sci; 2021; 17(2):635-650. PubMed ID: 33613118
[No Abstract] [Full Text] [Related]
15. The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development.
Sharp TV; Al-Attar A; Foxler DE; Ding L; de A Vallim TQ; Zhang Y; Nijmeh HS; Webb TM; Nicholson AG; Zhang Q; Kraja A; Spendlove I; Osborne J; Mardis E; Longmore GD
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19932-7. PubMed ID: 19060205
[TBL] [Abstract][Full Text] [Related]
16. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner.
Zou H; Zou R; Chen K; Zhu C; Tian X; You Y; He X
J Cell Biochem; 2018 Nov; 119(11):9217-9228. PubMed ID: 30105797
[TBL] [Abstract][Full Text] [Related]
17. MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1.
Shi Q; Zhou Z; Ye N; Chen Q; Zheng X; Fang M
Cancer Biomark; 2017 Dec; 20(4):539-546. PubMed ID: 28946554
[TBL] [Abstract][Full Text] [Related]
18. C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.
Shi Y; Chen J; Li Z; Zhang Z; Yu H; Sun K; Wang X; Song X; Wang Y; Zhen Y; Yang T; Lou K; Zhang Y; Zhang G; Hu Y; Ji J; Hui R
Oncogene; 2011 Sep; 30(39):4107-17. PubMed ID: 21499297
[TBL] [Abstract][Full Text] [Related]
19. LIMD1 antagonizes E2F1 activity and cell cycle progression by enhancing Rb function in cancer cells.
Mayank AK; Sharma S; Deshwal RK; Lal SK
Cell Biol Int; 2014 Jul; 38(7):809-17. PubMed ID: 24523249
[TBL] [Abstract][Full Text] [Related]
20. PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells.
Symonds JM; Ohm AM; Tan AC; Reyland ME
Oncotarget; 2016 Apr; 7(14):17905-19. PubMed ID: 26918447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
